Inhibiting PLK1 induces autophagy of acute myeloid leukemia cells via mammalian target of rapamycin pathway dephosphorylation
暂无分享,去创建一个
Guang-Hui Qian | Yanhong Li | Gang Li | Yiping Li | Jian Wang | Jian Pan | F. Fang | Shaoyan Hu | Zhiheng Li | Xing Feng | Weiqi He | Li-xiao Xu | Mei Li | Yanfang Tao | Jun Lu | Weiwei Du | Xiao-lu Li | Yi Xie | Yi Wu | Junli Ren | Yi-ping Li | Xiao-Lu Li
[1] Jing Wang,et al. Overexpression of PLK3 Mediates the Degradation of Abnormal Prion Proteins Dependent on Chaperone-Mediated Autophagy , 2016, Molecular Neurobiology.
[2] R. Davis,et al. Atg7 suppression enhances chemotherapeutic agent sensitivity and overcomes stroma-mediated chemoresistance in acute myeloid leukemia. , 2016, Blood.
[3] K. Coombes,et al. MLN0128, a novel mTOR kinase inhibitor, disrupts survival signaling and triggers apoptosis in AML and AML stem/ progenitor cells , 2016, Oncotarget.
[4] R. Dempsey,et al. Poststroke Induction of α-Synuclein Mediates Ischemic Brain Damage , 2016, The Journal of Neuroscience.
[5] N. Ahmad,et al. Plk1 Inhibitors in Cancer Therapy: From Laboratory to Clinics , 2016, Molecular Cancer Therapeutics.
[6] W. Gu,et al. Synergistic inhibition of colon cancer cell growth with nanoemulsion-loaded paclitaxel and PI3K/mTOR dual inhibitor BEZ235 through apoptosis , 2016, International journal of nanomedicine.
[7] L. Gachkar,et al. Expression analysis of BECN1 in acute myeloid leukemia: association with distinct cytogenetic and molecular abnormalities , 2016, International journal of laboratory hematology.
[8] M. Wetzler,et al. Polo-like kinase inhibitors in hematologic malignancies. , 2016, Critical reviews in oncology/hematology.
[9] K. Stegmaier,et al. Aberrant activation of the PI3K/mTOR pathway promotes resistance to sorafenib in AML , 2015, Oncogene.
[10] N. Hamdy,et al. Beclin-1 and hypoxia-inducible factor-1α genes expression: Potential biomarkers in acute leukemia patients. , 2016, Cancer biomarkers : section A of Disease markers.
[11] Wen-Qi Jiang,et al. Puquitinib mesylate (XC-302) induces autophagy via inhibiting the PI3K/AKT/mTOR signaling pathway in nasopharyngeal cancer cells , 2015, International journal of molecular medicine.
[12] Qiang Shi,et al. Activation of the AMPK-ULK1 pathway plays an important role in autophagy during prion infection , 2015, Scientific Reports.
[13] D. Ferguson,et al. Autophagy limits proliferation and glycolytic metabolism in acute myeloid leukemia , 2015, Cell Death Discovery.
[14] V. Kota,et al. Volasertib for AML: clinical use and patient consideration , 2015, OncoTargets and therapy.
[15] J. Cheong,et al. Induction of cytosine arabinoside-resistant human myeloid leukemia cell death through autophagy regulation by hydroxychloroquine. , 2015, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[16] I. Ganley,et al. Pharmacological Inhibition of ULK1 Kinase Blocks Mammalian Target of Rapamycin (mTOR)-dependent Autophagy* , 2015, The Journal of Biological Chemistry.
[17] Nazanin Heidari,et al. Targeting PI3K/AKT/mTOR network for treatment of leukemia , 2015, Cellular and Molecular Life Sciences.
[18] Chunyan Sun,et al. [Expression of autophagy related gene BECLIN-1 and number of autophagic vacuoles in bone marrow mononuclear cells from 40 myelodysplastic syndromes patients and their significance]. , 2015, Zhongguo shi yan xue ye xue za zhi.
[19] Huiting Zhou,et al. Molecular Targeting of the Oncoprotein PLK1 in Pediatric Acute Myeloid Leukemia: RO3280, a Novel PLK1 Inhibitor, Induces Apoptosis in Leukemia Cells , 2015, International journal of molecular sciences.
[20] P. Schöffski,et al. Discovery and development of the Polo-like kinase inhibitor volasertib in cancer therapy , 2014, Leukemia.
[21] D. Moon,et al. Synergistic antitumor effect of NVP-BEZ235 and sunitinib on docetaxel-resistant human castration-resistant prostate cancer cells. , 2014, Anticancer research.
[22] Xiaoying Lin,et al. YY1-MIR372-SQSTM1 regulatory axis in autophagy , 2014, Autophagy.
[23] E. V. Van Bockstaele,et al. Suppression of MAPK/JNK-MTORC1 signaling leads to premature loss of organelles and nuclei by autophagy during terminal differentiation of lens fiber cells , 2014, Autophagy.
[24] J. McCubrey,et al. Targeting phosphatidylinositol 3-kinase signaling in acute myelogenous leukemia , 2013, Expert opinion on therapeutic targets.
[25] Zhe Zhang,et al. Polo-like kinase 1 is overexpressed in renal cancer and participates in the proliferation and invasion of renal cancer cells , 2013, Tumor Biology.
[26] S. Milstien,et al. A specific sphingosine kinase 1 inhibitor attenuates airway hyperresponsiveness and inflammation in a mast cell-dependent murine model of allergic asthma. , 2013, The Journal of allergy and clinical immunology.
[27] Emmanuel Barillot,et al. Polo-like kinase 1: a potential therapeutic option in combination with conventional chemotherapy for the management of patients with triple-negative breast cancer. , 2013, Cancer research.
[28] N. Eissa,et al. Plk1 is upregulated in androgen-insensitive prostate cancer cells and its inhibition leads to necroptosis , 2012, Oncogene.
[29] Q. Zhan,et al. Reciprocal activation between PLK1 and Stat3 contributes to survival and proliferation of esophageal cancer cells. , 2012, Gastroenterology.
[30] A. Isacchi,et al. NMS-P937, an Orally Available, Specific Small-Molecule Polo-like Kinase 1 Inhibitor with Antitumor Activity in Solid and Hematologic Malignancies , 2012, Molecular Cancer Therapeutics.
[31] Yi Chen,et al. Identification of novel, potent and selective inhibitors of Polo-like kinase 1. , 2012, Bioorganic & Medicinal Chemistry Letters.
[32] T. Kawamoto,et al. TAK-960, a Novel, Orally Available, Selective Inhibitor of Polo-Like Kinase 1, Shows Broad-spectrum Preclinical Antitumor Activity in Multiple Dosing Regimens , 2011, Molecular Cancer Therapeutics.
[33] F. Berthold,et al. Polo-Like Kinase 1 is a Therapeutic Target in High-Risk Neuroblastoma , 2010, Clinical Cancer Research.
[34] A. Abdollahi,et al. Phenotype-assisted transcriptome analysis identifies FOXM1 downstream from Ras–MKK3–p38 to regulate in vitro cellular invasion , 2010, Oncogene.
[35] Christian Bailly,et al. Polo-like kinase 1 is overexpressed in acute myeloid leukemia and its inhibition preferentially targets the proliferation of leukemic cells. , 2009, Blood.
[36] F. Callera,et al. Lack of antileukemic activity of rapamycin in elderly patients with acute myeloid leukemia evolving from a myelodysplastic syndrome. , 2008, Leukemia research.
[37] M. Barbacid,et al. Cell cycle kinases in cancer. , 2007, Current opinion in genetics & development.
[38] Kiranmai Gumireddy,et al. ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent. , 2005, Cancer cell.
[39] Xiaoqi Liu,et al. Polo-like kinase (Plk)1 depletion induces apoptosis in cancer cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.